biotech / news / / The Manila Times
Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC) presented at the 2026 American Association for Cancer Research
Cadonilimab plus chemotherapy showed a median overall survival exceeding 23 months in locally advanced PDAC.
KEY POINTS
- Twelve-month overall survival rate reached 91.7% and 24-month rate was 44.1% for locally advanced disease.
- Objective response rate was 33.9% and disease control rate was 96.4% across the entire COMPASSION-26 population.
- No new safety signals were found, confirming the regimen's favorable and manageable safety profile.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →